以国际专利分类号A61P为基础，从发明专利视角对我国中药治疗适应证分布情况进行动态及静态分析，并将申请量、有效量最多的10组A61P小组名单与我国高死亡率疾病名单进行比较，以分析验证我国中药发明专利重点是否在高死亡率疾病上这一观点，并为中药治疗高死亡率疾病的研发方向与战略提出建议。我国中药研发重点基本关注在高死亡率疾病上，但治疗恶性肿瘤与精神障碍的除外；中药治疗消化系统疾病是优势方向。为此，在中药国际化标准化背景下，我国需加强中药治疗恶性肿瘤、精神障碍等病种方向的投入，发挥中药治疗消化系统疾病所具有的数量与质量优势，积极对外进行专利布局，同时重视技术评估在高质量高价值中药专利培育中的作用。

Based on the International Patent Classification (IPC) A61P, this paper analyzes the distributional therapeutic situation of Chinese materia medica (CMM) in China dynamically and statically from the perspective of invention patent, then the list of 10 groups of A61P with the largest amount of invention patents application and effective amount is compared with the list of high mortality diseases in China, so as to verify the idea whether the R&D focus of CMM is on high mortality diseases, and put forward suggestions for the R&D directions and strategies of CMM in the treatment of high mortality diseases. The research finds that the R&D of CMM mainly focuses on treating high mortality diseases, except for the malignant tumors and mental disorders. In addition, the intellectual achievement of CMM in the treatment of digestive system diseases is the dominant direction. Under the background of internationalization and standardization of CMM, China needs to strengthen the R&D investment direction of CMM in the treatment of malignant tumors, mental disorders and other fields. The quantity and quality advantages of CMM in the treatment of digestive system diseases will be of significance, thus it needs to actively carry out patent distribution abroad. The role of technical evaluation in the cultivation of high-quality and high-value patents should be attached importance.

R282.71

广州市哲学社会科学"十三五"规划2018年度课题（2018GZGJ66）；广州中医药大学广东省中医药健康服务与产业发展研究中心资助项目（2019ZDA01）